StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Q1 Launch update on Twitter and LinkedIn

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon Dec 18, 2020 11:06am

158 Views

Post# 32139858

RE:RE:RE:RE:RE:RE:Q1 Launch update on Twitter and LinkedIn

kingpine wrote: I think that once we get over $1.50 many investors will be interested in investing. 1:16 instead of 1:8 would have been a good idea. And the story would be different. But we're going to get there it's just going to take longer.

Yes, when you look at various climbers this past week like SPOR, NUMI, TRIP, HIVE, DMGI, HUT etc., the volume levels were off the chart as investors climbed on board and the share prices soared. The same thing will occur here if Aristotle gets the reception we hope.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading